The Bayh-Dole Coalition has raised alarms regarding a new NIH policy imposed by the Biden administration, warning it could stifle the commercialization of NIH inventions. The recent policy, requiring potential licensees to detail how they will ensure products are 'available, affordable, acceptable, and sustainable,' is seen as overly burdensome and contrary to the intent of the original Bayh-Dole Act. Critics argue that these requirements could complicate innovation and lead to a chilling effect on the development of critical therapies, with significant implications for public health and scientific advancement.
"This will have a dire impact on the commercialization of potentially life saving inventions made at NIH."- Joseph Allen
Collection
[
|
...
]